RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Guangdi Wang to Drug Evaluation, Preclinical

Back to Details
This is a "connection" page, showing publications Guangdi Wang has written about Drug Evaluation, Preclinical.
Guangdi Wang
Connection Strength
0.158
Drug Evaluation, Preclinical
  1. Zhong Q, Zhang C, Zhang Q, Miele L, Zheng S, Wang G. Boronic prodrug of 4-hydroxytamoxifen is more efficacious than tamoxifen with enhanced bioavailability independent of CYP2D6 status. BMC Cancer. 2015 Sep 09; 15:625.
    View in: PubMed
    Score: 0.128
  2. Strong AL, Ohlstein JF, Jiang Q, Zhang Q, Zheng S, Boue SM, Elliott S, Gimble JM, Burow ME, Wang G, Bunnell BA. Novel daidzein analogs enhance osteogenic activity of bone marrow-derived mesenchymal stem cells and adipose-derived stromal/stem cells through estrogen receptor dependent and independent mechanisms. Stem Cell Res Ther. 2014 Aug 28; 5(4):105.
    View in: PubMed
    Score: 0.030
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support